Literature DB >> 19640844

Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds.

Xiaoyi Deng1, Ramesh Gujjar, Farah El Mazouni, Werner Kaminsky, Nicholas A Malmquist, Elizabeth J Goldsmith, Pradipsinh K Rathod, Margaret A Phillips.   

Abstract

Malaria remains a major global health burden and current drug therapies are compromised by resistance. Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) was validated as a new drug target through the identification of potent and selective triazolopyrimidine-based DHODH inhibitors with anti-malarial activity in vivo. Here we report x-ray structure determination of PfDHODH bound to three inhibitors from this series, representing the first of the enzyme bound to malaria specific inhibitors. We demonstrate that conformational flexibility results in an unexpected binding mode identifying a new hydrophobic pocket on the enzyme. Importantly this plasticity allows PfDHODH to bind inhibitors from different chemical classes and to accommodate inhibitor modifications during lead optimization, increasing the value of PfDHODH as a drug target. A second discovery, based on small molecule crystallography, is that the triazolopyrimidines populate a resonance form that promotes charge separation. These intrinsic dipoles allow formation of energetically favorable H-bond interactions with the enzyme. The importance of delocalization to binding affinity was supported by site-directed mutagenesis and the demonstration that triazolopyrimidine analogs that lack this intrinsic dipole are inactive. Finally, the PfDHODH-triazolopyrimidine bound structures provide considerable new insight into species-selective inhibitor binding in this enzyme family. Together, these studies will directly impact efforts to exploit PfDHODH for the development of anti-malarial chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19640844      PMCID: PMC2785385          DOI: 10.1074/jbc.M109.028589

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Experimental assessment of differences between related protein crystal structures.

Authors:  G J Kleywegt
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-11

2.  Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis.

Authors:  R A Copeland; J Marcinkeviciene; T S Haque; L M Kopcho; W Jiang; K Wang; L D Ecret; C Sizemore; K A Amsler; L Foster; S Tadesse; A P Combs; A M Stern; G L Trainor; A Slee; M J Rogers; F Hobbs
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

Review 3.  Implications of protein flexibility for drug discovery.

Authors:  Simon J Teague
Journal:  Nat Rev Drug Discov       Date:  2003-07       Impact factor: 84.694

4.  Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects?

Authors:  A Ullrich; W Knecht; M Fries; M Löffler
Journal:  Eur J Biochem       Date:  2001-03

5.  Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites.

Authors:  I K Srivastava; J M Morrisey; E Darrouzet; F Daldal; A B Vaidya
Journal:  Mol Microbiol       Date:  1999-08       Impact factor: 3.501

Review 6.  Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.

Authors:  M M Goldenberg
Journal:  Clin Ther       Date:  1999-11       Impact factor: 3.393

7.  Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.

Authors:  S Liu; E A Neidhardt; T H Grossman; T Ocain; J Clardy
Journal:  Structure       Date:  2000-01-15       Impact factor: 5.006

8.  Divergent evolution of pyrimidine biosynthesis between anaerobic and aerobic yeasts.

Authors:  M Nagy; F Lacroute; D Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

9.  Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.

Authors:  G Lakaschus; M Löffler
Journal:  Biochem Pharmacol       Date:  1992-03-03       Impact factor: 5.858

10.  Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.

Authors:  Jeffrey Baldwin; Azizeh M Farajallah; Nicholas A Malmquist; Pradipsinh K Rathod; Margaret A Phillips
Journal:  J Biol Chem       Date:  2002-08-19       Impact factor: 5.157

View more
  37 in total

1.  Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.

Authors:  Ramesh Gujjar; Farah El Mazouni; Karen L White; John White; Sharon Creason; David M Shackleford; Xiaoyi Deng; William N Charman; Ian Bathurst; Jeremy Burrows; David M Floyd; David Matthews; Frederick S Buckner; Susan A Charman; Margaret A Phillips; Pradipsinh K Rathod
Journal:  J Med Chem       Date:  2011-05-12       Impact factor: 7.446

Review 2.  Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.

Authors:  Margaret A Phillips; Pradipsinh K Rathod
Journal:  Infect Disord Drug Targets       Date:  2010-06

3.  Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.

Authors:  Elumalai Pavadai; Farah El Mazouni; Sergio Wittlin; Carmen de Kock; Margaret A Phillips; Kelly Chibale
Journal:  J Chem Inf Model       Date:  2016-03-08       Impact factor: 4.956

Review 4.  Malaria medicines: a glass half full?

Authors:  Timothy N C Wells; Rob Hooft van Huijsduijnen; Wesley C Van Voorhis
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

5.  GMP synthase is essential for viability and infectivity of Trypanosoma brucei despite a redundant purine salvage pathway.

Authors:  Qiong Li; Christopher Leija; Filipa Rijo-Ferreira; Jun Chen; Igor Cestari; Kenneth Stuart; Benjamin P Tu; Margaret A Phillips
Journal:  Mol Microbiol       Date:  2015-07-04       Impact factor: 3.501

Review 6.  Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.

Authors:  Wim G J Hol
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-04-16       Impact factor: 1.056

7.  Hemozoin-free Plasmodium falciparum mitochondria for physiological and drug susceptibility studies.

Authors:  Michael W Mather; Joanne M Morrisey; Akhil B Vaidya
Journal:  Mol Biochem Parasitol       Date:  2010-07-30       Impact factor: 1.759

8.  Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.

Authors:  Sreekanth Kokkonda; Xiaoyi Deng; Karen L White; Farah El Mazouni; John White; David M Shackleford; Kasiram Katneni; Francis C K Chiu; Helena Barker; Jenna McLaren; Elly Crighton; Gong Chen; Inigo Angulo-Barturen; Maria Belen Jimenez-Diaz; Santiago Ferrer; Leticia Huertas-Valentin; Maria Santos Martinez-Martinez; Maria Jose Lafuente-Monasterio; Rajesh Chittimalla; Shatrughan P Shahi; Sergio Wittlin; David Waterson; Jeremy N Burrows; Dave Matthews; Diana Tomchick; Pradipsinh K Rathod; Michael J Palmer; Susan A Charman; Margaret A Phillips
Journal:  J Med Chem       Date:  2020-04-16       Impact factor: 7.446

Review 9.  1,2,4-Triazolo[1,5-a]pyrimidines in drug design.

Authors:  Killian Oukoloff; Bobby Lucero; Karol R Francisco; Kurt R Brunden; Carlo Ballatore
Journal:  Eur J Med Chem       Date:  2019-01-14       Impact factor: 6.514

10.  Reconstruction and flux-balance analysis of the Plasmodium falciparum metabolic network.

Authors:  Germán Plata; Tzu-Lin Hsiao; Kellen L Olszewski; Manuel Llinás; Dennis Vitkup
Journal:  Mol Syst Biol       Date:  2010-09-07       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.